Form 4: Passage Bio Executive Acquires Stock Options
SEC Form 4
Edgar B. Cale, General Counsel & Corporate Secretary of Passage Bio, Inc., reports the acquisition of employee stock options.
Summary
- On March 15, 2025, Edgar B. Cale, General Counsel & Corporate Secretary of Passage Bio, Inc., acquired 278,386 employee stock options.
- The exercise price of the options is $0.387.
- The options vest monthly, starting April 15, 2025, over a period of 48 months, contingent upon continued service to the company.
- The expiration date for these options is March 15, 2035.
- Following the transaction, Cale directly owns 278,386 derivative securities.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices and aligns interests with shareholders.
Positives
- The acquisition of stock options by a key executive suggests confidence in the company's future performance.
Industry Context
This is a standard practice for incentivizing executives in publicly traded companies, particularly in the biotech industry.
Stakeholder Impact
- The acquisition of stock options by an executive can align their interests with those of shareholders, potentially driving long-term value creation.
Key Dates
| Date | Description |
|---|---|
| 03/15/2025 | Date of the stock option transaction. |
| 04/15/2025 | Start date for monthly vesting of the stock options. |
| 03/15/2035 | Expiration date of the stock options. |
| 03/18/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.